Kuehne + Nagel and GSK sign long-term global logistics partnership contract
Kuehne + Nagel to run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company.
Kuehne + Nagel and GSK have signed an end-to-end global logistics partnership until 2021 that will see Kuehne + Nagel run the core business of transporting products from the raw materials supplier to trade customers for the leading global healthcare company.
The contract officially marks the commencement of a relationship which brings significant logistics alignment between the two companies; with Kuehne + Nagel providing skills, expertise and strategic capability to deliver enhanced value across GSK's global supply chain operations.
With numerous suppliers, a large number of manufacturing units and a variety of specific routes to patients and consumers in over one hundred countries; GSK requires a sophisticated and truly global end-to-end logistics solution. Kuehne + Nagel was selected as a partner due to the company's existing track record with GSK, strength in the industry, maturity of Integrated Logistics provision and significant investment strategy in pharmaceuticals and consumer products logistics. In all engagements the cultural fit and complementary approaches of both companies has been evident.
Detlef Trefzger, CEO of Kuehne + Nagel International AG, stated: "We are very excited about this long term collaboration with GSK. Our focus is to leverage existing experience and industry-specific solutions serving the pharmaceutical and consumer sector which will deliver incremental benefits to GSK. Our integrated logistics approach, comprising air, sea, overland services and Logistics Control Centres in four regional hubs will enable GSK's global supply chains to move to the next level of performance."
The new working relationship is a transformational development for both GSK and Kuehne + Nagel in its scale and ambition. It is one of Kuehne + Nagel's biggest customer awards and marks significant progress towards realising both GSK's ambition of a world class supply chain and Kuehne + Nagel's goal to be the leading provider of end-to-end solutions in the pharmaceutical and consumer sectors.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance